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How this Fits in 
Diagnostic coding for Chronic Kidney Disease (CKD) in the GP record is less than optimal. 
Absence of coding is associated with poorer blood pressure control and management of 
cardiovascular risk, observational data also demonstrate higher rates of unplanned hospital 
admission among uncoded cases. 
This project demonstrates that a rapid and sustained improvement in CKD coding can be 
achieved across clinical commissioning groups using a range of quality improvement 
techniques.   
Abstract 
Background 
Evidence from the UK national chronic kidney disease (CKD) audit in primary care shows 
that diagnostic coding in the electronic health record for CKD averages 70% with wide 
practice variation. Coding is associated with improvements to risk factor management, and 
there is evidence that CKD cases coded in primary care have lower rates of unplanned 
hospital admission.  
Aim 
To increase the diagnostic coding of CKD (stages 3-5) and key aspects of primary care 
management, including blood pressure to target and prescription of lipid lowering 
medication to reduce cardiovascular disease (CVD) risk. 
Design and Setting 
Prospective, controlled, cross sectional study set in four clinical commissioning groups 
(CCGs) in east London. 
Method 
Interventions to improve coding formed part of a larger system change to the delivery of 
renal services in both primary and secondary care in east London. These included 
dashboards with key performance indicators, searches to enable practices to identify un-
coded cases and monitor progress, and safety tools to identify cases with a falling estimated 
glomerular filtration rate (eGFR). This was supplemented with practice-based facilitation on 
using the quality improvement (QI) tools, and with education sessions. Additional renal 
specific clinical facilitation was provided for practices in the lowest decile of CKD coding.  
Quarterly anonymised data on CKD coding, blood pressure values and statin prescriptions  
were extracted from practice computer systems for a one year period pre and post the start 
of the intervention.  
Results 
All three intervention CCGs showed significant coding improvement over a one year period 
following the intervention (regression for post intervention trend p<0.001). The CCG with 
highest coding rates increased from 76% to 90% of CKD cases coded, the lowest coding CCG 
increased from 52% to 76%.  The comparison CCG showed no change in coding rates.  
Combined data from all practices in the intervention CCGs showed a significant increase in 
the proportion of cases with blood pressure achieving target levels (difference in proportion 
p<0.001) over the two year study period. Differences in statin prescribing were not 
significant.  
 
Conclusions 
Clinically important improvements to coding and management of CKD in primary care can 
be achieved by QI interventions which use shared data to track and monitor change 
supported by practice based facilitation. Alignment of clinical and CCG priorities and the 
provision of clinical targets, financial incentives and educational resource were additional 
important elements of the intervention.  
Background 
The estimated prevalence of Chronic Kidney Disease (CKD) stages 3-5 in the UK is 5-6% (1).  
Early identification of people with CKD in primary care, particularly among those with risk 
factors such as diabetes and hypertension, enables proactive management of blood 
pressure, cardiovascular risk and lifestyle factors and referral to specialist services where 
there is evidence of progressive disease (2). There is some evidence, albeit inconsistent (3)  
that progression of CKD can be delayed by reduction of blood pressure (4).  High rates of 
cardiovascular risk associated with CKD can be reduced by blood pressure control and the 
use of statins (5, 6). There is evidence that delivery of these interventions in primary care 
can be extended through the target population by the use of quality improvement tools 
including local audits of CKD management, feedback and education.  (7, 8).  
Delivering improvements to the management of CKD in primary care involves a range of 
organisational and clinical negotiations. There is a continuing debate on whether the early 
identification of CKD is clinically important, or whether it is an example of over diagnosis 
and prone to over treatment (9, 10). This contributes to ambivalence among clinicians 
around disclosing a diagnosis of CKD to individuals. In turn this subverts the opportunities 
for patient engagement with lifestyle changes which lie at the heart of early management 
(11).  Additional challenges include the uncertainty of best clinical management in older and 
multimorbid patients (12, 13), and the complexity of the Read codes used for labelling CKD 
stage in GP computer systems.  
Adding a diagnostic CKD Read code to the electronic health record (EHR) enables regular 
recall for review, and provides a marker for the increased clinical scrutiny necessary for 
better management – in particular blood pressure control, an offer of lipid lowering 
medication, and the avoidance of hazardous prescribing.  The first report from the UK 
national CKD audit in primary care (1) demonstrated that on average 70% of biochemically 
confirmed cases of CKD (stages 3-5) were given a diagnostic Read code. There was wide 
variation between practices, with the proportion of CKD cases un-coded ranging between 
0% to 80%.  Further analysis based on data from the NCKD audit demonstrates an 
association between coding status and management activity in primary care. Coded cases 
had higher rates of blood pressure to target, statin use, assessment of urinary albumin 
creatinine ratio and immunisations (14). 
The second part of the national CKD audit linked hospital data on outcomes to the cases 
identified in primary care (15). There were associations between lack of coding in primary 
care with higher rates of unplanned hospital admissions, acute kidney injury admissions and 
deaths. The magnitude of the difference in admission rates between coded and un-coded 
patients increases as kidney function declines. As the eGFR declines below 40ml/min the 
unplanned admission rate doubles for un-coded cases (15). 
Translating evidence into routine clinical practice faces multiple challenges, including 
understanding professional knowledge and beliefs and an appreciation of the structure, 
organisation and context of healthcare in any given locality. Some of the key strategies for 
change management described by Kotter (16) were reflected in planning the 
implementation of this programme. These include:  building the case for change and 
forming a guiding coalition which includes both clinicians and managers, empowering others 
to act on the programme by the provision of education, comparative performance data and 
quality improvement (QI) tools, creating early wins for the programme and consolidating 
the new approach into work as usual to ensure sustainability.  
Aims 
This quality improvement programme aimed to modify health professional behaviour to 
increase the recorded diagnosis of CKD (stages 3-5) and improve key aspects of primary care 
management including blood pressure control and provision of lipid lowering medication for 
cardiovascular risk reduction. 
  
Methods 
Study design and setting 
This prospective, controlled, cross sectional study was set in east London primary care 
between 2016-2018. All 130 GP practices in three inner east London CCGs (City and 
Hackney, Newham and Tower Hamlets) received all elements of the intervention. The 37 
practices in a fourth CCG (Waltham Forest) did not  start the intervention package until one 
year later and acted as a comparison group. In the 2011 UK Census, almost half of the 
population in each of these CCGs was recorded to be of non-white ethnic origin (17),  and 
the English indices of deprivation 2015 show that all three intervention localities fall in the 
lowest decile for social deprivation in England (18). 
 
Intervention 
The intervention was conceived as a renal learning health system (19), in which data from all 
parts of the system are used as feedback to improve both the future organisation and 
clinical performance within it. The interventions which supported CKD coding were part of a 
larger system change to the delivery of renal care, which encompassed the patient pathway 
from diagnostic identification and management in primary care through to attendance at 
the nephrology outpatient clinic.  
The system wide changes to the delivery of renal care had four components.  
a) A package of IT tools which support practices to identify patients requiring diagnostic 
coding, improvements to blood pressure and cardiovascular management, and alerts to 
identify cases with a falling estimated glomerular filtration rate (eGFR). Regular practice 
facilitation on clinical data management as offered routinely by the Clinical Effectiveness 
Group (CEG) supported this package (https://www.qmul.ac.uk/blizard/ceg/).  Additional 
renal specific clinical facilitation, which focussed on the importance of CKD coding, CVD and 
BP management, was offered to practice teams in the lowest decile of CKD coding. 
b) Renal education and case discussions for general practitioners and practice nurses at 
CCG, cluster and practice events in all participating CCGs. 
c) A virtual CKD hospital clinic enabling nephrologists to view the primary care electronic 
health record (EHR), with informed patient consent, and document advice in the shared 
record available for all primary care clinicians to see. The clinic had a short wait time 
(approximately 7 days – previously the average wait was 64 days) with the aim of providing 
timely clinical advice for GPs in the EHR, and triaging the minority of patients who required 
further investigation into out-patient clinics. 
d) Specialist renal nurse led patient education sessions for those referred into the service. 
Within this framework the interventions which primarily targeted the improvement of CKD 
coding and management included: practice based education sessions, the package of 
computerised quality improvement tools with facilitation, data sharing across practices and 
CCG provision of financial incentives for target achievement at practice and cluster level. 
Important contextual background to the intervention is that all 130 practices in the three 
intervention CCGs had prior experience of working with clinical data entry templates, quality 
improvement tools and performance dashboards developed by the Clinical Effectiveness 
Group and the associated practice facilitation supporting the effective use of primary care 
data for better management of long term conditions. (20) All three intervention clinical 
commissioning groups (CCGs) supported the renal programme with a range of practice 
targets and financial incentives built into the enhanced service element of general practice 
contracts during the intervention period. 
The control CCG began implementation of the virtual CKD clinic during the intervention 
year, and had clinician education sessions, but had no quality improvement tools or regular 
facilitation.  
Data collection 
Renal function, expressed as the estimated glomerular filtration rate (eGFR), was calculated 
from recorded creatinine using the four variable modification of diet in renal disease 
(MDRD) equation, which adjusts for gender and Black ethnicity. (21) The study population 
with CKD (stages 3-5) in each CCG was identified from eGFR values of <60 ml/min/1.73m2 in 
the two most recent readings at least three months apart. 
Demographic and clinical data were obtained for all adults over the age of 18 with 
biochemical evidence of CKD.  Patient-level variables included, age, sex, ethnicity, latest 
blood pressure values and diagnostic Read codes for diabetes mellitus, hypertension and 
CKD.  All data were anonymised, and managed according to UK NHS information governance 
requirements.   
Anonymised practice coding and primary care management data were collected on a 
quarterly basis through EMIS Web. (https://www.emishealth.com/products/emis-
web?tab=primary-caref) This was collated into CCG and practice level dashboards and 
shared with commissioners and practice staff. Quarterly data from the control CCG was not 
available prior to April 2016.  Reflecting the open cohort design, the population at each 
quarter differed from the previous one, reflecting the additions and losses from GP 
registered lists. A quarterly CKD service newsletter was also circulated providing further 
feedback to practices on coding performance.  
All statistical analyses were performed using Stata v.14. (https://www.stata.com/)  Linear 
regression analysis was used to examine the change in trend of the proportion of patients 
with a CKD Read code pre and post intervention for each CCG. Proportions with ‘BP to 
target’ and statin prescriptions were examined, pre and post intervention. ‘BP to target’ 
refers to all patients with biochemical evidence of CKD with a BP <140/70 mm/Hg, or 
<130/80 mm/Hg for those with diabetes or a urinary albumin creatinine ratio (uACR) >70 
mg/g . For non-diabetic patients with no recorded uACR values, we used the higher BP 
target.   A two-level multilevel logistic regression model was used to observe the univariate 
and adjusted odds ratios (OR) in patients on statins and patients with a BP to target, 
comparing intervention and control CCGs at the beginning and end of the study period. 
Standard errors were adjusted by clustering by practice. 
The study conformed to the Standards for Quality Improvement Reporting Excellence 
(SQUIRE V2.0) guidance(22). 
 
Results 
Data were collected for 167 practices, of which 130 were in the intervention CCGs and 37 
were in the control group. At the final data collection point (April 2018) the number of 
people with biochemical evidence of CKD (stages 3-5) across all practices was 21,428. 
Baseline CKD coding data were collected quarterly for each of the three intervention CCGs 
for one year prior to the start of the intervention.  All three intervention CCGs showed 
significant coding improvement over a one year period following the intervention 
(regression for post intervention trend p<0.001). The CCG which started with the highest 
coding rates increased from 76% to 90% of CKD cases coded, the CCG with lowest coding 
rates increased from 52% to 76%. (see figure 1.) The control CCG showed no change in 
coding over the two year period (April 2016 to April 2018).  Variation in practice 
performance was also reduced. (figure 2) 
Changes in the proportion of CKD cases with BP to target, and those prescribed lipid-
lowering medication over the two year period were examined for all people with CKD in the 
three intervention CCGs combined. There was a significant increase in the proportion of 
people with blood pressure achieving target levels (difference in proportion p<0.001) 
differences in statin prescribing were not significant, see table 1. 
The management of BP and CVD risk (statin prescribing) between control and intervention  
CCGs was compared at baseline (April 2016) and at the end of the study period (April 2018). 
At both baseline and endpoint the intervention CCGs performed better than the control 
CCG.  Endpoint comparison shows BP to target (adjusted OR 1.48, 95%CI 1.29 to 1.71) and 
statin prescribing (adjusted OR 1.41, 95%CI 1.23 to 1.60), see tables 2-4.  
 
Differences in BP and statin prescribing were also examined by each participating CCG. This 
demonstrates almost twice the odds of statin use in those with CKD in Tower Hamlets 
compared with Waltham Forest (adjusted OR 1.95 95% CI 1.69 to 2.24) and almost twice the 
odds of blood pressure to target in those with CKD in City and Hackney compared with 
Waltham Forest (adjusted OR 1.92, 95% CI 1.64 to 2.24) (see tables in appendix).  
The average difference in mean systolic BP for people with CKD between the combined 
intervention CCGs and the control CCGs was 2.2 mmHg (intervention CCGs 130.5 SD 15, 
control CCG 132.7 SD 15.5, t-test for comparison of means, p<0.001) see appendix table 3. 
  
Discussion 
Main findings 
Over a two year study period a linked set of interventions to improve CKD coding and 
management, embedded within a system wide renal service change, has significantly 
increased CKD coding among general practices in three geographically contiguous CCGs. This 
has been accompanied by significant improvements in management of BP to target. 
In comparison to the control CCG practices in the two intervention CCGs had a significantly 
higher odds of achieving BP to target and prescribing statins for CVD protection. These are 
two aspects of care for people with renal impairment which make an important  difference 
to the risk of a CVD event. (23) However these differences were also present at the start of 
the observation period and cannot be attributed to the intervention. 
The average difference in BP between the people with CKD in the intervention and control 
group was 2.2 mmHg. Such changes to whole population blood pressure control may reduce 
the progression of kidney disease, particularly for those with proteinuria. (4) 
 
Strengths and limitations 
A strength of this study is the application of this complex service change to whole health 
economies, rather than to selected practices. The inclusion of a natural control CCG 
strengthens the impact of the intervention. In the financial year 2017-18 there was partial 
change to the renal service in the control CCG. Some diffusion of the intervention was likely, 
as the service change was widely reported by CCGs at sustainability and transformation plan 
(STP) events. This would be expected to reduce the between group differences. 
The involvement of consultant nephrologists and specialist renal nurses in all elements of 
service delivery was a key aspect of the success of this programme, which builds on the core 
elements of quality improvement and change management which the Clinical Effectiveness 
Group has delivered in other clinical domains. (24-26) The importance of demonstrating 
early programme success, by regular feedback of coding improvement, reflects the use of 
the ‘strategy for change’ described by Kotter.(16) 
 
This was a pragmatic programme evaluation, recognising variation in the way the 
intervention was implemented in each of the three CCGs, for example some minor 
differences in the choice of practice level achievement targets and the delivery of financial 
incentives for coding. The decision to concentrate specialist renal nurse facilitation in 
Newham CCG, which had the lowest baseline coding rates, also creates unevenness in 
implementation of the different elements of the programme.  The importance of 
recognising these contextual differences between CCGs in their approach to implementing 
and incentivising change within constituent practices is an essential consideration in future 
decisions on scaling up such interventions. Differences in context may determine the 
effectiveness of implementation, and hence the likelihood of achieving similar changes to 
that reported in this study.  
Comparisons with existing literature 
Other studies have demonstrated the existing shortfall in the primary care management of 
CKD in comparison to national guidance, Hull et al in 2011 found that 50% of those with a 
diagnosis of hypertension and an eGFR<60 ml/min/1.73m2 had a BP <130/80 (27), while Van 
Gelder et al 2016, in the Netherlands, found coding rates of 31% and BP managed to target 
in 43% (28), Fraser and others have demonstrated the burden of co-morbidities among 
those with CKD managed in primary care. (29) 
Previous trials and quality improvement strategies, which show evidence of effectiveness 
for improving BP management, have largely focussed on selected high risk populations with 
CKD rather than unselected primary care populations. (30)  A pragmatic trial in primary care 
using audit-based education found a similar 2mmHg reduction in systolic BP comparing 
practices exposed to guidelines and prompts or to usual care.(8)  
A number of studies have demonstrated associations between CKD and risk of all cause 
hospitalisation.(31)  A recent matched primary care cohort found twice the risk of admission 
for heart failure and a fivefold risk of AKI admission among those with CKD stage 3B in 
comparison to no CKD. (32)  This suggests that a focus on improved coding and 
management for those with CKD and associated conditions such as heart failure could 
contribute to a reduction in hospital admissions.  
 
Implications for practice 
This report forms part of the evaluation of a system change in the delivery of care for people 
with CKD across primary and secondary settings in east London.  
The learning renal health system we describe has implications for clinical practice and 
patient safety on a national scale. If all CCGs in England adopted a similar approach to 
improve CKD coding and the management of BP in the CKD population, this would have a 
significant effect on the risk of CVD events, and may possibly reduce hospital admissions.   
 
The three intervention CCGs had a well-developed working relationship with the CEG (20) 
and the range of primary care support services they offer. Historically the clinicians and 
managers in these CCGs have been early adopters of evidence based clinical change of value 
to patients and the health economy. Such interventions require an IT infrastructure to 
enable the delivery of practice dashboards and the facilitation required to engage practice 
teams in using IT tools to support clinical change. They also require a stable and respectful 
relationship between managers, clinicians and secondary care specialists to engage in data 
sharing for learning across the whole patient pathway, and hence utilise to the full the 
opportunities for service change and development. 
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Figure 1. Coding improvement across 3 intervention CCGs in east London compared to the 
control CCG (Waltham Forest) 
 
 
 
 
The red arrows indicate the start of the intervention. Tower Hamlets in April 2016, Newham and City & 
Hackney in October 2016. Data from Waltham Forest was only available from April 2016. 
 
 
Regression for post intervention trend 
CCG Coding change/quarter P value 95% confidence intervals 
Tower Hamlets 2.85% P<0.001 1.73 to 3.96 
City and Hackney 2.76% P<0.001 1.96 to 3.55 
Newham 5.03% P<0.001 3.76 to 6.28 
 
 
 
 
 
 
 
 
 
 
  
Figure 2.  Practice CKD coding: improvement and reduction in practice variation Newham 
CCG 2016-18. 
 
 
 
Each dot represents a practice. The funnel plot on the L shows practice coding performance at the start of the 
intervention. The funnel plot on the R shows coding performance at the end of the project.  
The tracer plots on the R hand side show the changes in coding rates, tracked over 2 years, by 8 practices which 
started in the lowest coding quintile.   
  
 Table 1. Changes in the proportion of people with CKD achieving BP to target1 and statin 
prescribing in the three intervention CCGs over the two-year study period. 
 
 
  Pre-intervention: 
January 2016 
(N=16298) 
Post intervention: 
April 2018 
(N=15811) 
P-value2 
Blood pressure to 
target: N=16,300  
Mean proportion 0.52 0.54 P <0.001 
Statin use: 
N=16,300  
Mean proportion 0.75 0.76 p = 0.064 
 
1 All CKD patients with BP <140/90 and <130/80 if diabetes/uACR>70 
2 A test of proportion was conducted to compare proportions one year pre- and post-intervention 
 
  
Table 2. Characteristics of all study patients with biochemical evidence of CKD (Stages 3-5) 
at the end of the study period 
 
  Total All 
 N (%)  
21428  (100) 
Waltham Forest  
N (%)  
5617 (26.2) 
Tower 
Hamlets N (%) 
4933 (23.0) 
Newham  
N (%)  
7250 (33.8) 
City & Hackney 
N (%)  
3628 (16.9) 
Gender  
     
Female 12200 (56.9) 3222 (57.4) 2798 (56.7) 4124 (56.9) 2056 (56.7) 
Male  9226 (43.1) 2393 (42.6) 2135 (43.3) 3126 (43.1) 1572 (43.3) 
Age group  
     
<60 3510 (16.4) 797 (14.2) 749 (15.2) 1381 (19.0) 583 (16.1) 
60 - 69 4103 (19.2) 977 (17.4) 956 (19.4) 1555 (21.5) 615 (17.0) 
70 - 79  6245 (29.1) 1730 (30.8) 1346 (27.3) 2159 (29.8) 1010 (27.8) 
≥80 7570 (35.3) 2113 (37.6) 1882 (38.2) 2155 (29.7) 1420 (39.1) 
      
Ethnic group 
     
White 10624 (49.6) 3213 (57.2) 2588 (52.5) 2941 (40.6) 1882 (51.9) 
South Asian 6069 (28.3) 1042 (18.6) 1782 (36.1) 2846 (39.3) 399 (11.0) 
Black  2999 (14.0) 657 (11.7) 330 (6.7) 1068 (14.7) 944 (26.0) 
Other 851 (4.0) 174 (3.1) 134 (2.7) 289 (4.0) 254 (7.0) 
Not stated 885 (4.1) 531 (9.5) 99 (2.0) 106 (1.5) 149 (4.1)       
Diabetes 
     
No 12477 (58.2) 3612 (64.3) 2682 (54.4) 4131 (57.0) 2052 (56.6) 
Yes 8951 (41.8) 2005 (35.7) 2251 (45.6) 3119 (43.0) 1576 (43.4)       
Hypertension  
     
No 5167 (24.1) 1529 (27.2) 1227 (24.9) 1746 (24.1) 665 (18.3) 
Yes 16261 (75.9) 4088 (72.8) 3706 (75.1) 5504 (75.9) 2963 (81.7) 
      
Statins 
     
No 5784 (27.0) 1932 (34.4) 913 (18.5) 1999 (27.6) 940 (25.9) 
Yes 15644 (73.0) 3685 (65.6) 4020 (81.5) 5251 (72.4) 2688 (74.1)       
BP to target1 
     
No 
10396 (48.5) 3026 (53.9) 2185 (44.3) 3666 (50.6) 1519 (41.9) 
Yes 11032 (51.5) 2591 (46.1) 2748 (55.7) 3584 (49.4) 2109 (58.1) 
Mean 
Systolic 
BP (SD) 131.1 (15.2) 132.7 (15.5) 130.6 (15.5) 131.1 (14.8) 129.2 (14.7) 
 
1All CKD patients with BP <140/90 and <130/80 if diabetes/uACR>70 
 
 
 
 
 
 
 Table 3. Odds ratios for statin use in people with CKD. Comparing intervention CCGs with 
control CCG at baseline and one-year post intervention1 
 
 
Baseline comparison (March 2016) Comparison one-year post intervention 
 CCG 
 N Adjusted OR 
(95% CI) 
 CCG 
 N  Adjusted OR 
(95% CI) 
Without 
intervention 
4909 1 
Without 
intervention 
5617 1 
With 
intervention 
16059 1.53 (1.35-1.73) 
With 
intervention 
15811 1.41 (1.23-1.60) 
 
¹Adjusted for age, sex, ethnicity, presence of diabetes, hypertension and CKD coding.  
Standard errors are adjusted for clustering by practice. 
 
 
 
 
Table 4. Odds ratios for blood pressure to target1 in people with CKD, comparing 
intervention CCGs with control CCG at baseline and one-year post intervention2 
  
 
Baseline comparison (March 2016) Comparison one-year post intervention  
 CCG 
 N Adjusted OR 
(95% CI) 
 CCG 
 N  Adjusted OR 
(95% CI) 
Without 
intervention 
4909 1 
Without 
intervention 
5617 1 
With 
intervention 
16059 1.65 (1.43-1.89) 
With 
intervention 
15811 1.48 (1.29-1.71) 
 
1 All CKD patients with BP <140/90 and <130/80 if diabetes/uACR>70 
2Adjusted for age, sex, ethnicity, presence of diabetes, hypertension and CKD coding.  
Standard errors are adjusted for clustering by practice  
 
 
 
  
Appendix Table 1. Odds ratios for statin use in people with CKD, comparing individual 
intervention CCGs with control CCG at one year after the intervention1 
 
 
N Unadjusted 
OR (95% CI) 
p-value Adjusted2 OR 
 (95% CI) 
p-value 
CCG      
Waltham Forest 5617 1.0  1.0  
Tower Hamlets 4933 2.25 (1.92-2.62) <0.001 1.95 (1.69-2.24) <0.001 
Newham 7250 1.34 (1.17-1.54) <0.001 1.16 (1.02-1.32) 0.018 
City & Hackney 3628 1.48 (1.27-1.73) <0.001 1.34 (1.17-1.55) <0.001       
Age group (years) 
     
<60 3510 1.0 
 
1.0 
 
60 - 69 4103 3.03 (2.74-3.35) <0.001 2.47 (2.21-2.75) <0.001 
70 - 79 6245 4.29 (3.90-4.71) <0.001 3.42 (3.09-3.80) <0.001 
≥80 7570 2.87 (2.63-3.13) <0.001 2.29 (2.07-2.52) <0.001       
Gender      
Female 12200 1.0               1.0  
Male 9226 1.37 (1.29-1.46) <0.001 1.33 (1.24-1.42) <0.001       
White 10624 1.0              1.0  
South Asian 6069 1.73 (1.59-1.88) <0.001 1.33 (1.21-1.47) <0.001 
Black 2999 0.99 (0.90-1.09) 0.887 0.69 (0.62-0.76) <0.001 
Other 851 1.01 (0.86-1.19) 0.882 0.82 (0.69-0.98) 0.030 
Not stated 885 0.50 (0.43-0.58) <0.001 0.65 (0.55-0.76) <0.001       
      
Diabetes 
     
No 12477 1.0 
 
1.0 
 
Yes 8951 5.76 (5.32-6.23) <0.001 4.67 (4.29-5.07) <0.001       
Hypertension 
     
No 5167 1.0 
 
1.0 
 
Yes 16261 2.95 (2.76-3.16) <0.001 2.27 (2.10-2.45) <0.001       
Coded 
     
No 5191 1.0 
 
1.0 
 
Yes 16237 1.93 (1.79-2.08) <0.001 1.32 (1.21- 1.43) <0.001 
 
¹Adjusted for age, sex, ethnicity, prevalence of diabetes, hypertension and practice coding rates. Standard errors are 
adjusted for clustering by practice. 
 
Appendix Table 2. Odds ratios for blood pressure to target1 in people with CKD, comparing 
each intervention CCG with the control CCG at one year post intervention2.  
  N Unadjusted 
OR (95% CI) 
p-value Adjusted2 OR  
(95% CI) 
p-value 
CCG           
Waltham 
Forest  
5617 1.0   1.0   
Tower Hamlets 4933 1.52 (1.32-1.75) <0.001 1.61 (1.38-1.87) <0.001 
Newham  7250 1.12 (0.99-1.27) 0.083 1.16 (1.01-1.34) 0.039 
City & Hackney 3628 1.69 (1.47-1.95) <0.001 1.92 (1.64-2.24) <0.001 
            
Diabetes           
No 12477 1.0   1.0   
Yes 8951 0.32 (0.30-0.32) <0.001 0.31 (0.29-0.33) <0.001 
            
Hypertension            
No 5167 1.0   1.0   
Yes 16261 0.75 (0.71-0.80) <0.001 0.90 (0.84-0.96) 0.003 
            
CKD Coded           
No 5191 1.0   1.0   
Yes 16237 0.96 (0.90-1.03) 0.25 1.14 (1.06-1.23) 0.001 
            
Gender            
Female 12200 1.0   1.0   
Male  9226 1.06 (1.00-1.12) 0.055 1.16 (1.09-1.23) <0.001 
            
Age group 
(years) 
          
<60 3510 1.0   1.0   
60 - 69 4103 0.96 (0.87-1.05) 0.327 1.18 (1.07-1.30) 0.001 
70 - 79  6245 0.98 (0.90-1.07) 0.699 1.22 (1.12-1.34) <0.001 
≥80 7570 1.00 (0.92-1.09) 0.992 1.15 (1.05-1.26) 0.002 
            
Ethnic group           
White 10624 1.0   1.0   
South Asian 6069 0.76 (0.71-0.81) <0.001 1.08 (1.00-1.16) 0.062 
Black  2999 0.60 (0.55-0.66) <0.001 0.76 (0.70-0.84) <0.001 
Other 851 0.88 (0.76-1.02) 0.085 1.05 (0.76-1.02) 0.551 
 
1 All CKD patients with BP <140/90 and <130/80 if diabetes/uACR≥70 
2Adjusted for age, sex, ethnicity, diabetes, hypertension and coding. Standard errors are adjusted for clustering by practice.  
 
 
 
 
Appendix Table 3. Mean systolic BP (SD) for people with CKD post intervention. 
Comparing intervention CCGs with control CCG. 
 
 
  All 
Waltham 
Forest (Control) 
Tower 
Hamlets Newham 
City and 
Hackney 
Intervention 
CCGs 
p-
value 
Mean BP          
Systolic BP 131.1 (15.2) 132.7 (15.5) 130.6 (15.5) 131.1 (14.8) 129.2 (14.7) 130.5 (15.0) <0.001 
        
Diabetic or 
uACR≥70         
Systolic BP 131.2 (15.1) 132.9 (15.3) 131.1 (15.6) 131.3 (14.6) 129.2 (14.6) 130.7 (15.0) <0.001 
        
No diabetes, 
uACR≤70         
Systolic BP 130.9 (15.2) 132.6 (15.6) 130.1 (15.3) 130.9 (15.0) 129.2 (14.7) 130.2 (15.1) <0.001 
        
 
 
